Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05820672 · ClinicalTrials.gov registry record

A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA

A clinical trial of Growth Hormone Deficiency, sponsored by Ascendis Pharma Endocrinology Division A/S.

Recruiting
Registry status
900
Enrollment target
20
Study locations

NCT05820672 is a study of Growth Hormone Deficiency that is actively recruiting participants, run by Ascendis Pharma Endocrinology Division A/S. The registered enrollment target is 900 participants, above the 331-participant average among 16 other Growth Hormone Deficiency trials with a reported enrollment target (172% higher). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05820672, a study of Growth Hormone Deficiency, is actively recruiting participants, sponsored by Ascendis Pharma Endocrinology Division A/S.

RECRUITING
Registry status
900 participants
Enrollment target
20
Study locations

Study Summary

The goal of this study is to genrate evidence on long-term effectiveness and safety of SKYTROFA (lonapegsomatropin) in patients with growth hormone deficiency under routine clinical care

Conditions Studied

Growth Hormone Deficiency

Interventions

  • OTHER No intervention

Study Locations (20)

California

  • Ascendis Investigational Site - Orange
  • Ascendis Investigational Site - Sacramento
  • Ascendis Investigational Site - San Francisco

Florida

  • Ascendis Investigational Site - Orlando
  • Ascendis Investigational Site - Orlando
  • Ascendis Investigational Site - Tampa

New Hampshire

  • Ascendis Investigational Site - Lebanon
  • Ascendis Investigational Site - Manchester

Arizona

  • Ascendis Investigational Site - Phoenix

Colorado

  • Ascendis Pharma Investigational Site - Centennial

District of Columbia

  • Ascendis Investigational Site - Washington D.C.

Georgia

  • Ascendis Investigational Site - Sandy Springs

Idaho

  • Ascendis Investigational Site - Boise

Trial Details

FieldValue
Enrollment Target 900 participants
Start Date 2023-03-20
Est. Completion 2033-03

Sponsor

Ascendis Pharma Endocrinology Division A/S

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05820672

The ClinicalTrials.gov registry entry for NCT05820672 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 900 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 331-participant average among 16 other Growth Hormone Deficiency trials with a reported enrollment target (172% higher). The listed sponsor is Ascendis Pharma Endocrinology Division A/S, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Growth Hormone Deficiency appearing as the primary indexed condition, and to 1 intervention - of which No intervention is the first listed.

NCT05820672 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Florida, New Hampshire.

Frequently Asked Questions

What is clinical trial NCT05820672 about?

NCT05820672 is a clinical study titled "A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA". The goal of this study is to genrate evidence on long-term effectiveness and safety of SKYTROFA (lonapegsomatropin) in patients with growth hormone deficiency under routine clinical care

What is the current status of trial NCT05820672?

This trial is currently recruiting. The enrollment target is 900 participants. The study started on 2023-03-20. Estimated completion is 2033-03.

What conditions does trial NCT05820672 study?

This clinical trial studies the following conditions: Growth Hormone Deficiency.

What interventions are being tested in trial NCT05820672?

The interventions under investigation include: No intervention (OTHER).

Who is sponsoring clinical trial NCT05820672?

This trial is sponsored by Ascendis Pharma Endocrinology Division A/S, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05820672 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Growth Hormone Deficiency

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Growth Hormone Deficiency

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.